WO2024037667A3 - Composé hétérocyclique à noyaux fusionnés, son procédé de préparation et son application - Google Patents

Composé hétérocyclique à noyaux fusionnés, son procédé de préparation et son application Download PDF

Info

Publication number
WO2024037667A3
WO2024037667A3 PCT/CN2023/124951 CN2023124951W WO2024037667A3 WO 2024037667 A3 WO2024037667 A3 WO 2024037667A3 CN 2023124951 W CN2023124951 W CN 2023124951W WO 2024037667 A3 WO2024037667 A3 WO 2024037667A3
Authority
WO
WIPO (PCT)
Prior art keywords
fused ring
heterocyclic compound
ring heterocyclic
ahr
preparation
Prior art date
Application number
PCT/CN2023/124951
Other languages
English (en)
Chinese (zh)
Other versions
WO2024037667A2 (fr
Inventor
张所明
Original Assignee
德明药泰生物技术（深圳）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德明药泰生物技术（深圳）有限公司 filed Critical 德明药泰生物技术（深圳）有限公司
Publication of WO2024037667A2 publication Critical patent/WO2024037667A2/fr
Publication of WO2024037667A3 publication Critical patent/WO2024037667A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé hétérocyclique à noyaux fusionnés représenté par la formule I suivante, un isomère optique, une substance deutériée, un promédicament ou un sel pharmaceutiquement acceptable de ceux-ci, une composition pharmaceutique comprenant le composé hétérocyclique à noyaux fusionnés substitués, et une utilisation de ce composé en tant qu'inhibiteur de la voie du AhR. Selon la présente invention, le composé hétérocyclique à noyaux fusionnés peut être combiné avec AhR et inhiber les fonctions et les trajets de signaux contrôlés par AhR, de telle sorte que la croissance et la prolifération de cellules cancéreuses et le caractère invasif de cellules tumorales peuvent être affectés. Par conséquent, le composé hétérocyclique à noyaux fusionnés substitué selon la présente invention peut être utilisé pour inhiber la croissance de cellules cancéreuses et inhiber la métastase et l'invasion de cellules tumorales.
PCT/CN2023/124951 2022-08-19 2023-10-17 Composé hétérocyclique à noyaux fusionnés, son procédé de préparation et son application WO2024037667A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211000595.1 2022-08-19
CN202211000595.1A CN117624168A (zh) 2022-08-19 2022-08-19 稠环杂环类化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
WO2024037667A2 WO2024037667A2 (fr) 2024-02-22
WO2024037667A3 true WO2024037667A3 (fr) 2024-04-25

Family

ID=89940817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/124951 WO2024037667A2 (fr) 2022-08-19 2023-10-17 Composé hétérocyclique à noyaux fusionnés, son procédé de préparation et son application

Country Status (2)

Country Link
CN (1) CN117624168A (fr)
WO (1) WO2024037667A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831600A (zh) * 2017-04-21 2020-02-21 金恩医疗公司 吲哚ahr抑制剂和其用途
US20210079001A1 (en) * 2018-02-06 2021-03-18 Ideaya Biosciences, Inc. Compounds and methods for the modulation of ahr
CN113272305A (zh) * 2018-10-16 2021-08-17 医肯纳肿瘤学公司 吲哚ahr抑制剂及其用途
CN114181208A (zh) * 2020-09-15 2022-03-15 山东轩竹医药科技有限公司 三并环类AhR抑制剂及其用途
CN114369097A (zh) * 2020-10-15 2022-04-19 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114456178A (zh) * 2021-01-13 2022-05-10 重庆华森制药股份有限公司 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831600A (zh) * 2017-04-21 2020-02-21 金恩医疗公司 吲哚ahr抑制剂和其用途
US20210079001A1 (en) * 2018-02-06 2021-03-18 Ideaya Biosciences, Inc. Compounds and methods for the modulation of ahr
CN113272305A (zh) * 2018-10-16 2021-08-17 医肯纳肿瘤学公司 吲哚ahr抑制剂及其用途
CN114181208A (zh) * 2020-09-15 2022-03-15 山东轩竹医药科技有限公司 三并环类AhR抑制剂及其用途
CN114369097A (zh) * 2020-10-15 2022-04-19 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114456178A (zh) * 2021-01-13 2022-05-10 重庆华森制药股份有限公司 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法

Also Published As

Publication number Publication date
CN117624168A (zh) 2024-03-01
WO2024037667A2 (fr) 2024-02-22

Similar Documents

Publication Publication Date Title
MX2022006475A (es) Compuestos triciclicos sustituidos.
WO2019173082A8 (fr) L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
WO2007137030A3 (fr) Dérivés d'alcanes azabicycliques substitués à bicyclohétérocycle fusionné
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
HUP0303891A2 (hu) Gyógyhatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
WO2021012049A8 (fr) Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
WO2020210320A8 (fr) L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
AU2021308209A8 (en) Isoquinoline compounds and their use in treating ahr imbalance
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2022016516A (es) Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.
WO2024037667A3 (fr) Composé hétérocyclique à noyaux fusionnés, son procédé de préparation et son application
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2021014458A (es) Compuestos triciclicos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23854562

Country of ref document: EP

Kind code of ref document: A2